BOSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS ...

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced the achievement of the first ...

Additional Cerevance Presentations at AAN 2025The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...

Merck & Co's earlier efforts to find new therapies for Alzheimer's disease resulted in failure, but the company is returning to the field via an R&D alliance with UK biotech Cerevance that will ...

BOSTON & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance ...

Data supports once a day dosing of CVN766 in future studies BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central ...